D-0094-2023 Class III Terminated
FDA drug recall D-0094-2023 was initiated by Camber Pharmaceuticals, Inc on Dec 6, 2022 and is designated Class III. Reason for recall: Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content The recall status is terminated (terminated Mar 15, 2024).
Recall details
- Product Type
- Drugs
- Report Date
- Dec 21, 2022
- Initiation Date
- Dec 6, 2022
- Termination Date
- Mar 15, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Lacosamide Oral Solution, USP, CV, 10mg/mL, packaged in 200 mL bottle, Rx Only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, Manufactured By: HETERO LABS LIMITED, Jeedimetla, Hyderabad - 500 055, India, NDC 31722-627-26
Reason for recall
Failed Excipient Specifications: out of specification result observed for p-Hydroxybenzoic Acid content
Distribution pattern
USA Nationwide
Code information
Lot#: E222200, E222199, Exp 05/2024; E222228, Exp 06/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0094-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026